Rectal Diseases |
|
|
Clinical Trial: Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer
This study is no longer recruiting patients.
|
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug, giving the drugs in different ways, and combining chemotherapy with radiation therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus fluorouracil and leucovorin before surgery given with or without fluorouracil and leucovorin after surgery in patients with locally advanced rectal cancer.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| stage III rectal cancer adenocarcinoma of the rectum recurrent rectal cancer childhood gastrointestinal cancer mucinous adenocarcinoma of the rectum stage II rectal cancer | Drug: fluorouracil Drug: leucovorin calcium | Phase III |
MedlinePlus related topics: Cancer; Cancer Alternative Therapy; Colorectal Cancer; Digestive Diseases
Study Type: Interventional
Study Design: Treatment
Official Title: Phase III Randomized Study of Preoperative Radiotherapy plus Fluorouracil/Leucovorin with vs without Postoperative Fluorouracil/Leucovorin in Locally Advanced Adenocarcinoma of the Rectum
Study start: September 1993
OBJECTIVES: I. Assess the local recurrence rate, cost-benefit ratio, and acute and late toxicity associated with concomitant preoperative radiotherapy and fluorouracil/leucovorin (5-FU/CF) in patients with locally advanced adenocarcinoma of the rectum. II. Compare the relapse rate, survival rate, disease-free interval, and cost-benefit ratio associated with 6 courses of postoperative 5-FU/CF vs. no further treatment in these patients.
PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by tumor stage, age, type of surgery, and participating institution. Patients are randomly assigned to one of two groups. The first group receives radiotherapy to the tumor over 5 weeks and concomitant fluorouracil/leucovorin for 5 consecutive days on the first and fifth weeks. Four to six weeks later, patients undergo complete resection, followed upon recovery by fluorouracil/leucovorin every 4 weeks for 6 courses. The second group receives preoperative chemoradiotherapy followed by surgery, as above, with no postoperative treatment. Patients are followed for survival.
PROJECTED ACCRUAL: A total of 774 patients will be entered on this multicenter study.
Eligibility
Ages Eligible for Study: up to 75 Years
Criteria
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
- Histologically confirmed adenocarcinoma or mucinous adenocarcinoma of the rectum; Distal limit of tumor no higher than 12 cm from the anal verge on proctoscopy
- Locally advanced (T3-4 M0) tumor by one of the following: Partial fixation; Complete stenosis; Invasion beyond the muscular stratum on transrectal ultrasound
--Prior/Concurrent Therapy--
- Not specified
--Patient Characteristics--
- Age: 75 and under
- Performance status: WHO 0 or 1
- Hematopoietic: WBC greater than 3,000; Platelets greater than 130,000
- Hepatic: Not specified
- Renal: Creatinine less than 1.4 mg/dL
- Cardiovascular: No unstable angina; No cardiac decompensation
- Other: No prior or concurrent malignancy
Location Information
Italy
Ospedale St. Santa Chiara, Pisa, 56100, Italy
Luca Cionini, Study Chair, Chemo Prevention Unit
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: May 2004
Last Updated: October 13, 2004
Record first received: November 1, 1999
ClinicalTrials.gov Identifier: NCT00002896
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -

